Company: TEM
Filing Date: 2025-02-24
Form Type: 10-K
Source: 0000950170-25-025603
Chunk: 575

Company: Tempus AI, Inc.
Filing Date: 2025-02-24
Form: 10-K
Item: Item 1B
Chunk 575
---
 the latest equity financing price. The warrant was terminated for no consideration on December 31, 2024. 

        As of December 31,

        2024

        2023

        2022

        Stock options outstanding

        —

        210,000

        210,000

        Convertible preferred stock

        —

        63,525,953

        62,692,927

        AstraZeneca warrant

        —

        1,744,991

        1,744,991

        Mpirik holdback liability

        —

        8,724

        —

        SEngine holdback liability

        —

        41,436

        —

        Unvested RSUs

        6,873,974

        —

        —

        Allen & Company warrant

        —

        150,000

        —

        Total potentially dilutive shares

        6,873,974

        65,681,104

        64,647,918

       As disclosed in Note 11, the RSUs issued prior to the IPO include a liquidity event performance condition prior to vesting. As such, as of December 31, 2023 and 2022, these are treated as contingently issuable shares and are excluded from potentially dilutive shares as the liquidity event performance condition was not yet satisfied. As the liquidity event performance condition was satisfied upon completion of the IPO, as of December 31, 2024, these shares are included in potentially dilutive shares. As disclosed in Note 12, contingent upon certain financing events, the Amended Note will be converted to shares at the holder’s option, based on the amount outstanding at the maturity date, which is subject to reduction based on services used by us prior to the maturity date. As such, these are treated as contingently issuable shares and will be excluded from potential dilutive impact. As disclosed in Note 10, the Company’s Series G-3 Preferred, Series G-4 Preferred and Series G-5 Preferred contain embedded conversion features resulted in the issuance of additional shares of Class A common stock upon completion of the IPO. The number of shares issued related to these features was dependent upon the IPO price. As such, prior to the IPO, these are treated as contingently issuable shares. Subsequent to the completion of the IPO in June 2024, the additional shares of Class A common stock are included in the weighted-average common shares